Ahead of the Bell: Quantum BioPharma (QNTM) Is On The Top Of Our Must-Watch List

*Sponsored by Quantum BioPharma Ltd. Krypton Street Announces Quantum BioPharma (QNTM) As Its Next Potential Breakout Idea For Friday 12/20/2024! Quantum BioPharma (NASDAQ: QNTM) Comes Backed By Several  Potential Catalysts Including: Under the Radar: Quantum BioPharma (NASDAQ: QNTM)’s market cap under $6.5 Mn highlights how it remains largely unnoticed despite  its recent progress. Tiny Float: With fewer than 1.6 Mn shares available, Quantum BioPharma Ltd. (NASDAQ: QNTM)’s small float could lead to significant swings if demand begins to shift. Analyst Confidence: Singular Research’s $12.80 price target reflect  over 300% upside from yesterday's $3.18 open. December 20, 2024 Dear Reader, A pivotal breakthrough in healthcare has recently been achieved by Quantum BioPharma (NASDAQ: QNTM), advancing the fight against multiple sclerosis.  The company’s Phase 1 trial for Lucid-21-302 (Lucid-MS) has gained safety committee approval to proceed with dosing its second cohort.   Through its subsidiary, HUGE Biopharma Australia Pty Ltd., Quantum BioPharma continues to demonstrate remarkable progress in reshaping neurological treatments. This comes after thorough evaluation of safety and pharmacokinetic data from the first cohort—an achievement that underscores Quantum BioPharma Ltd. (NASDAQ: QNTM)’s commitment to safety and scientific rigor. Following the successful review of data from the first cohort, the trial's safety review committee has recommended moving forward with the next phase of dosing. Dr. Andrzej Chruscinski, Vice-President of Scientific and Clinical Affairs at Quantum, expressed the team's enthusiasm, noting that dosing for the second cohort is expected to begin in the coming days. This advancement is not merely a checkpoint in the clinical trial timeline—it’s a signal that Quantum BioPharma Ltd. (NASDAQ: QNTM) is steadily building momentum in its quest to lead the future of neurological treatments.  Keep reading to see why Quantum BioPharma Ltd. (NASDAQ: QNTM) is #1 on our watchlist this morning.  Quantum BioPharma Ltd. (NASDAQ: QNTM) recently launched a massive $700Mn lawsuit against several well-known institutions, accusing them of manipulation through "spoofing."   This announcement could set the stage for significant developments ahead.  Quantum BioPharma (NASDAQ: QNTM), with its market cap currently under $6.5M, may have been flying under Wall Street's radar—until now. Quantum BioPharma (NASDAQ: QNTM) dropped to $3.15 yesterday, entering what some consider “Severely Oversold” territory.  The Relative Strength Index (RSI), a trusted momentum indicator, is often the benchmark for identifying such conditions.  The RSI measures the speed and magnitude of price changes on a scale from 0 to 100, with readings below 30 signaling oversold conditions and readings above 70 indicating overbought levels.  As of 12/19, Quantum BioPharma (NASDAQ: QNTM)’s RSI numbers tell the story clearly.  The 9-day RSI sits at a low 19.80%, well below the oversold threshold. The 14-day RSI reads 27.97%, also in oversold territory, while the 20-day RSI at 34.30% remains close enough to suggest the potential for a reversal. What makes this even more compelling is the company’s exceptionally small float—fewer than 1.6 Mn shares, according to FinViz. When supply is this limited, even modest changes in demand can lead to significant volatility.  Adding to the excitement, Singular Research recently reiterated its bullish stance on Quantum BioPharma (NASDAQ: QNTM), setting a target of $12.80 per share. From today’s opening of $3.18, this suggests a potential upside of over 300%, signaling strong confidence in the company’s future. With its small float, RSI trending in what appears to be oversold territory, analyst coverage, and potential for growth, Quantum BioPharma (NASDAQ: QNTM) checks all the boxes we look for in a profile. Taking a Look at Quantum BioPharma (NASDAQ: QNTM) Quantum BioPharma (NASDAQ: QNTM) is leading the way in biopharmaceutical innovation, focusing on groundbreaking treatments for neurodegenerative and metabolic disorders, along with solutions for al-co-hol misuse.  With a diverse portfolio of candidates at various stages of development, the company is committed to addressing some of the most complex medical challenges. Through its subsidiary, Lucid Ps-ych-eceu-ticals Inc., Quantum BioPharma (NASDAQ: QNTM) is making significant progress with its lead compound, Lucid-MS, which plays a key role in the company’s mission to combat serious disorders affecting many people worldwide. One of their most promising initiatives, Lucid-MS, is a patented chemical entity designed to target multiple sclerosis (MS), a chronic, often disabling disease that affects approximately 2.8Mn people globally.  The multiple sclerosis therapeutic market is projected to grow from $21B in 2024 to $38B by 2032, underscoring the increasing need for effective treatments for this debilitating condition.  Lucid-MS is designed to address the underlying cause of MS by preventing and reversing myelin degradation.  Myelin is a protective sheath that covers nerve fibers, and its degradation is a key mechanism in the development of multiple sclerosis.  Preclinical models have shown that Lucid-MS is a neuroprotective compound with the potential to halt or reverse myelin damage, offering hope for improved outcomes for those affected by MS and other neurodegenerative conditions. Revolutionizing Al-co-hol Detoxification Quantum BioPharma (NASDAQ: QNTM) is making notable advancements in the al-co-hol detox space with the development of unbuzzd™, a product designed to boost mental alertness and aid detoxification after al-co-hol consumption.  This innovative solution addresses a pressing public health issue, blending scientific research with practical applications in al-co-hol metabolism. In 2023, unbuzzd™ was introduced to the market by Celly Nutrition Corp., a spin-off of Quantum BioPharma (NASDAQ: QNTM), with the company retaining a 25.71% stake.  The product, created by industry leaders from Coca-Cola and Celsius Holdings, has already secured a major distribution agreement with FUSION Distribution Group, bringing unbuzzd™ to Puerto Rico, the Caribbean, and parts of Central and South America.  Currently available as Ready-to-Mix powder sticks on Amazon, unbuzzd™ will soon be available in Ready-to-Drink cans.  With distribution set to expand through major retailers like Walmart and Costco, unbuzzd™ is positioned to transform the al-co-hol detox market by providing a much-needed solution for consumers seeking to metabolize al-co-hol faster and enhance mental clarity. Endorsed by Kevin Harrington, one of the original "Sharks" on Shark Tank and a seasoned entrepreneur in health and wellness, unbuzzd™ has attracted significant attention for its potential impact.  Harrington, renowned for identifying groundbreaking products, believes unbuzzd™ could change how society approaches al-co-hol consumption and detoxification. Harrington remarked on the product’s potential, noting that unbuzzd™ could offer a vital solution for those who consume al-co-hol, with the ability to reduce its harmful effects and improve lives on a large scale. In his testimonial, Harrington recalled a real-life example, saying, “I saw someone intoxicated take this product. Within minutes, their demeanor shifted, and their blood al-co-hol levels dropped. unbuzzd™ has the power to revolutionize the al-co-hol detox space.” With a strong focus on advancing solutions for multiple sclerosis, neurodegenerative diseases, and al-co-hol misuse, Quantum BioPharma (NASDAQ: QNTM) continues to solidify its role in biopharmaceutical innovation. As the company expands its portfolio of transformative treatments, its ongoing progress in these areas warrants close attention. 7 Reasons Why Quantum BioPharma (NASDAQ: QNTM) is #1 On Our Watchlist This Morning… 1. Under-the-Radar Growth Potential: Despite its recent advancements, Quantum BioPharma (NASDAQ: QNTM) market cap remains under $6.5 Mn, making it appear to be a severely overlooked player. 2. Tiny Float: With fewer than 1.6Mn shares available, Quantum BioPharma (NASDAQ: QNTM)’s small public float could lead to the potential for significant swings if demand begins to shift.  3. Technical Indicators: RSI readings suggest Quantum BioPharma (NASDAQ: QNTM) is headed towards “oversold territory”, often signaling potential for a reversal. 4. Advancing MS Clinical Trials: The Phase 1 trial for Lucid-21-302 (Lucid-MS) has received ethics approval to advance to the next stage. 5. Expanding MS Market: The multiple sclerosis market is projected to grow from $21B in 2024 to $38B by 2032. 6. Momentum Behind unbuzzd™: Backed by endorsements and international distribution, unbuzzd™ is scaling with plans to reach major retailers. 7. Analyst Coverage: Singular Research’s $12.80 price target suggests over 300% upside from the current $3.18 price. Here’s Why to Consider Adding Quantum BioPharma (NASDAQ: QNTM) to Your Radar This Week… Quantum BioPharma (NASDAQ: QNTM) is shaping up to be a standout in a field that thrives on innovation and progress. With a market cap under $6.5 Mn, it’s easy to see how this company could be flying under the radar—but that won’t last. A float of fewer than 1.6 Mn shares, combined with RSI indicators signaling the potential for oversold conditions, supports why (QNTM) is at the top of our watchlist. The company’s progress in advancing its Phase 1 trial for Lucid-MS aligns perfectly with the rapidly growing multiple sclerosis market, which is projected to nearly double in size over the next decade. Adding to its momentum is the international scaling of unbuzzd™, a product gaining traction with major endorsements and expanding distribution. Singular Research’s $12.80 target further underscores the confidence growing around Quantum BioPharma (NASDAQ: QNTM).   Now’s the time to take a look at (QNTM). Don’t wait for the opening bell when you can start your research early. We have (QNTM) up on our screen right now and watching it like a hawk so keep a look out for my next update. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired by TD Media LLC for a period beginning on 12/19/2024 and ending on 12/20/2024 to publicly disseminate information about (QNTM:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”) to disseminate information about (QNTM:US) via digital communications. These Funds were part of the funds that TD Media LLC received from Quantum BioPharma Ltd., the issuer. To date, including under the previously described agreement, Media 1717 LLC has been paid thirty-five thousand USD (“Funds”) for (QNTM:US). Neither Media 1717 LLC, TD Media LLC and their member own shares of (QNTM:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/qntm/

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice